[go: up one dir, main page]

LUC00103I2 - - Google Patents

Download PDF

Info

Publication number
LUC00103I2
LUC00103I2 LU00103C LUC00103C LUC00103I2 LU C00103 I2 LUC00103 I2 LU C00103I2 LU 00103 C LU00103 C LU 00103C LU C00103 C LUC00103 C LU C00103C LU C00103 I2 LUC00103 I2 LU C00103I2
Authority
LU
Luxembourg
Application number
LU00103C
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00103(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of LUC00103I1 publication Critical patent/LUC00103I1/fr
Publication of LUC00103I2 publication Critical patent/LUC00103I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU00103C 2007-11-27 2019-02-18 LUC00103I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99057407P 2007-11-27 2007-11-27
US9438808P 2008-09-04 2008-09-04
PCT/US2008/084988 WO2009070740A2 (fr) 2007-11-27 2008-11-26 Nouveaux composés et nouvelles compositions et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
LUC00103I1 LUC00103I1 (fr) 2019-02-19
LUC00103I2 true LUC00103I2 (fr) 2019-12-27

Family

ID=40679222

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00103C LUC00103I2 (fr) 2007-11-27 2019-02-18

Country Status (35)

Country Link
US (8) US8084483B2 (fr)
EP (2) EP2217577B1 (fr)
JP (3) JP5099794B2 (fr)
KR (2) KR101291643B1 (fr)
CN (3) CN101918377A (fr)
AR (1) AR069753A1 (fr)
AU (2) AU2008329673C1 (fr)
BR (1) BRPI0819847B1 (fr)
CA (1) CA2706858C (fr)
CL (1) CL2008003529A1 (fr)
CY (1) CY2019010I1 (fr)
DK (1) DK2217577T3 (fr)
EA (2) EA018193B3 (fr)
EC (1) ECSP10010310A (fr)
ES (1) ES2513390T3 (fr)
HR (1) HRP20140950T1 (fr)
HU (1) HUS1900009I1 (fr)
IL (1) IL205974A (fr)
LT (1) LTPA2019003I1 (fr)
LU (1) LUC00103I2 (fr)
MA (1) MA31936B1 (fr)
ME (2) ME01294B (fr)
MX (1) MX2010005776A (fr)
MY (1) MY147370A (fr)
NO (1) NO2016016I1 (fr)
NZ (4) NZ601774A (fr)
PL (1) PL2217577T3 (fr)
PT (1) PT2217577E (fr)
RS (1) RS53569B1 (fr)
SG (1) SG183721A1 (fr)
SI (1) SI2217577T1 (fr)
TN (1) TN2010000237A1 (fr)
TW (1) TWI415840B (fr)
WO (1) WO2009070740A2 (fr)
ZA (1) ZA201003769B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
CN101083987B (zh) 2004-08-25 2011-01-26 阿迪亚生命科学公司 作为HIV逆转录酶抑制剂的S-三唑基α-巯基乙酰苯胺
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2328879A4 (fr) * 2008-09-04 2012-05-09 Ardea Biosciences Inc Composés, compositions, et procédés d'utilisation correspondants pour moduler des taux d'acide urique
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2349258A1 (fr) * 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1-cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-yl- thio)acétamido-3-chlorobenzoïque et ses sels de qualité pharmaceutique
WO2010048592A1 (fr) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
WO2010071865A1 (fr) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432468A2 (fr) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Procédés pour moduler des taux d'acide urique
EP2432774A4 (fr) * 2009-05-20 2013-01-02 Ardea Biosciences Inc Composés, compositions et procédés pour moduler des taux d'acide urique
US8524754B2 (en) * 2010-01-08 2013-09-03 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof
WO2011126852A2 (fr) * 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Traitement de la goutte
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
US9212135B2 (en) 2010-06-16 2015-12-15 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP2627331A4 (fr) * 2010-10-15 2014-03-12 Ardea Biosciences Inc Méthodes de traitement de l'hyperuricemie et de maladies liées
CN103200821A (zh) * 2010-10-28 2013-07-10 Mapi医药公司 非布索坦的多晶型物
SG190902A1 (en) 2010-12-30 2013-07-31 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
WO2012122532A2 (fr) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions et méthodes de traitement de l'hyperuricémie
WO2012162323A1 (fr) * 2011-05-24 2012-11-29 Ardea Biosciences, Inc. Hypertension et hyperuricémie
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
JP6025853B2 (ja) 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
ES2698396T3 (es) * 2011-11-04 2019-02-04 Cymabay Therapeutics Inc Métodos para tratar los brotes de gota
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
CN104066323A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 用于治疗患者亚群中痛风的方法
AR089812A1 (es) * 2012-01-27 2014-09-17 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
TWI666205B (zh) * 2012-11-14 2019-07-21 日商帝人製藥股份有限公司 吡啶衍生物
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
ES2668721T3 (es) 2013-05-13 2018-05-21 Shanghai Hengrui Pharmaceutical Co. Ltd. Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo
CN105263913B (zh) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 硫代1,2,4‑三唑衍生物及其制备方法
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN104447589B (zh) * 2013-11-20 2017-01-11 广东东阳光药业有限公司 一种尿酸调节剂的制备方法及其中间体
WO2015075561A2 (fr) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Formes cristallines de lésinurad et son sel de soude
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
WO2015095703A1 (fr) * 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Nouveaux sels et co-cristaux de lésinurad
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN106036135A (zh) * 2014-07-25 2016-10-26 许伟琦 一种防止结石、快速排结石的药物、组合物、兽药
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104529848A (zh) * 2014-11-10 2015-04-22 安徽万邦医药科技有限公司 一种1-环丙基-4-异硫氰酰基萘的合成方法
CA2972065A1 (fr) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methodes et formulations pour l'administration transdermique
CN107108478B (zh) * 2014-12-29 2020-04-24 日本化学药品株式会社 Urat1抑制剂
CN105985295B (zh) * 2015-02-17 2018-11-20 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104710374A (zh) * 2015-04-14 2015-06-17 安徽省逸欣铭医药科技有限公司 一种痛风新化合物及制备方法、用途及其药物制剂
CN106187926B (zh) * 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2016203436A1 (fr) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Dispersions amorphes et solides amorphes de lesinurad et leur préparation
EP3112334A1 (fr) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Procédé de fabrication de 1-cyclopropyl-naphthalènes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017033963A1 (fr) * 2015-08-26 2017-03-02 株式会社スタージェン Agent de renforcement de l'atp dans les cellules
WO2017036884A1 (fr) 2015-08-28 2017-03-09 Sandoz Ag Co-cristal de lésinurad, forme libre/ester éthylique de lésinurad
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
EP3380970B1 (fr) * 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
ES2911284T3 (es) 2015-12-28 2022-05-18 Shanghai Fochon Pharmaceutical Co Ltd Derivados de indolizina, composición y métodos de uso
WO2017147270A1 (fr) * 2016-02-24 2017-08-31 Ardea Biosciences, Inc. Atropisomères de dérivé triazole
CN107176930B (zh) * 2016-03-11 2020-12-01 广东赛烽医药科技有限公司 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基]乙酸化合物及其应用
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
WO2017202291A1 (fr) * 2016-05-23 2017-11-30 南京明德新药研发股份有限公司 Thiophène, son procédé de fabrication, et application pharmaceutique correspondante
CN106074540B (zh) * 2016-06-10 2018-10-16 江西博屾医疗器械有限公司 一种用于高尿酸血症治疗的药物组合物及其应用
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
US10633351B2 (en) 2016-06-17 2020-04-28 Medshine Discovery Inc. Halogenated compound and axially chiral isomer thereof
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
EP3281941B1 (fr) 2016-08-11 2019-07-24 Zentiva K.S. Procédé de préparation d'acide 2-(5-bromo-4-(1-cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ythio) acétique
CZ2016611A3 (cs) * 2016-09-30 2018-05-09 Zentiva, K.S. Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
US10513500B2 (en) 2016-11-10 2019-12-24 Apotex Inc. Crystalline forms of Lesinurad
CA3043640A1 (fr) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Milieu de type plasma humain
CN108164471B (zh) * 2016-12-07 2019-09-13 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (fr) 2017-04-19 2018-05-02 Química Sintética, S.A. Forme amorphe de lésinurad et ses procédés de préparation
CN108947919B (zh) * 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EP3681479B1 (fr) * 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Bicarbonate de sodium pour utilisation dans le traitement de la goutte et de troubles associés
EP3712148B1 (fr) 2017-11-23 2021-07-07 Medshine Discovery Inc. Formes cristallines d'un inhibiteur d'urat1 et leurs procédés de préparation
EP3498697A1 (fr) 2017-12-12 2019-06-19 Química Sintética, S.A. Nouveaux sels et polymorphes de lesinurad
WO2019114838A1 (fr) * 2017-12-15 2019-06-20 南京明德新药研发股份有限公司 Cristal et sel de composé de 4-(naphtalén-1-yl)-4h-1,2,4-triazole et son procédé de préparation
JP7422087B2 (ja) 2018-05-09 2024-01-25 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 光活性化された作用物質を使用してポリヌクレオチドアレイを合成する方法
IL317123A (en) 2018-08-27 2025-01-01 Regeneron Pharma Using Raman Spectroscopy for Downstream Purification
CN109369783B (zh) * 2018-11-30 2021-09-10 昆明医科大学 一种多肽rdp1及其提纯方法与应用
CN111320588B (zh) * 2018-12-14 2024-02-09 上海奥博生物医药股份有限公司 一种纯化Lesinurad的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006101A (en) 1932-07-05 1935-06-25 Meaf Mach En Apparaten Fab Nv Reversing mechanism for dry gas meters
NL7112373A (fr) * 1970-09-25 1972-03-28
US4198513A (en) * 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
JPS5641637B2 (fr) 1973-11-26 1981-09-29
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
JP2000510164A (ja) 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
DE69943247D1 (de) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
BR9915129A (pt) 1998-11-12 2001-08-07 Neurocrine Biosciences Inc Antagonistas do receptor de crf e processos relacionados aos mesmos
WO2000037471A1 (fr) 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: ligands pour recepteurs cerebraux gaba
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
CN1494528A (zh) 2001-03-02 2004-05-05 ʷ��˿�������ȳ�ķ���޹�˾ 作为逆转录酶抑制剂的二苯酮
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2462132C (fr) 2002-01-28 2010-08-10 Fuji Yakuhin Co., Ltd. Compose 1,2,4-triazole
AU2003222648A1 (en) 2002-05-13 2003-12-02 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
EP1545483B1 (fr) 2002-08-23 2011-04-06 Ardea Biosciences, Inc. Inhibiteurs non nucleosidiques de transcriptases inverses
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
EP1698348A4 (fr) 2003-11-14 2008-02-27 Human Cell Systems Inc Remede curatif ou preventif des troubles vasculaires et de l'hypertension et son procede de criblage
WO2005060711A2 (fr) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Procedes de traitement d'un trouble
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
EP1723123A4 (fr) 2004-03-08 2009-12-02 Wyeth Corp Modulateurs de canaux ioniques
EP1751120A4 (fr) * 2004-05-25 2010-05-05 Metabolex Inc Triazoles substitués comme modulateurs de ppar et méthodes de préparation
US20060013556A1 (en) * 2004-07-01 2006-01-19 Thomas Poslinski Commercial information and guide
CN101083987B (zh) * 2004-08-25 2011-01-26 阿迪亚生命科学公司 作为HIV逆转录酶抑制剂的S-三唑基α-巯基乙酰苯胺
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007077042A1 (fr) 2006-01-06 2007-07-12 Topotarget Switzerland Sa Nouveau procede de traitement de la goutte ou la pseudogoutte
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
CA2653217A1 (fr) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Procede pour traiter des troubles proliferants associes a des produits protooncogenes
EP2026797A2 (fr) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Méthode pour traiter un lymphome non hodgkinien
CA2662242C (fr) 2006-09-07 2012-06-12 Amgen Inc. Composes benzo-fusionnes destines a etre utilises dans le traitement de troubles metaboliques
EP1939181A1 (fr) 2006-12-27 2008-07-02 sanofi-aventis Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase
US20090042887A1 (en) 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (fr) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
WO2010071865A1 (fr) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés
WO2012162323A1 (fr) 2011-05-24 2012-11-29 Ardea Biosciences, Inc. Hypertension et hyperuricémie

Also Published As

Publication number Publication date
EP2842948A1 (fr) 2015-03-04
MY147370A (en) 2012-11-30
ECSP10010310A (es) 2010-07-30
KR20120084787A (ko) 2012-07-30
US20160221970A1 (en) 2016-08-04
ME01294B (fr) 2013-06-20
US8283369B2 (en) 2012-10-09
US8084483B2 (en) 2011-12-27
US20120164222A1 (en) 2012-06-28
RS53569B1 (sr) 2015-02-27
SI2217577T1 (sl) 2014-11-28
EP2217577A2 (fr) 2010-08-18
NO2016016I2 (no) 2016-08-17
HK1180337A1 (en) 2013-10-18
PL2217577T3 (pl) 2015-01-30
CA2706858A1 (fr) 2009-06-04
MA31936B1 (fr) 2010-12-01
ZA201003769B (en) 2011-02-23
EA018193B3 (ru) 2014-07-30
CY2019010I2 (el) 2019-11-27
NZ595035A (en) 2012-11-30
CN103058944B (zh) 2015-08-05
TN2010000237A1 (en) 2011-11-11
EP2217577B1 (fr) 2014-08-06
AU2012203172B2 (en) 2013-10-10
NO2016016I1 (no) 2016-08-17
US20090197825A1 (en) 2009-08-06
TWI415840B (zh) 2013-11-21
IL205974A (en) 2015-03-31
JP2014196373A (ja) 2014-10-16
AR069753A1 (es) 2010-02-17
EA018193B1 (ru) 2013-06-28
US10183012B2 (en) 2019-01-22
NZ601774A (en) 2013-07-26
US20110293719A1 (en) 2011-12-01
HUS1900009I1 (hu) 2019-03-28
AU2012203172A1 (en) 2012-06-21
DK2217577T3 (da) 2014-10-20
US20170281601A1 (en) 2017-10-05
NZ601786A (en) 2014-02-28
ME01996B (me) 2015-05-20
JP5099794B2 (ja) 2012-12-19
TW200927733A (en) 2009-07-01
US8546437B2 (en) 2013-10-01
CN103058944A (zh) 2013-04-24
WO2009070740A2 (fr) 2009-06-04
EA201000897A1 (ru) 2010-12-30
BRPI0819847A2 (pt) 2020-10-06
CN102643241A (zh) 2012-08-22
KR20100085195A (ko) 2010-07-28
LUC00103I1 (fr) 2019-02-19
US20140005136A1 (en) 2014-01-02
CL2008003529A1 (es) 2009-11-27
NZ585583A (en) 2011-09-30
US8357713B2 (en) 2013-01-22
EA201270666A1 (ru) 2012-12-28
ES2513390T3 (es) 2014-10-27
PT2217577E (pt) 2014-10-20
CN101918377A (zh) 2010-12-15
SG183721A1 (en) 2012-09-27
WO2009070740A3 (fr) 2009-08-13
CA2706858C (fr) 2013-12-24
BRPI0819847B1 (pt) 2022-01-11
KR101291643B1 (ko) 2013-08-01
AU2008329673B2 (en) 2012-04-12
US20110268801A1 (en) 2011-11-03
IL205974A0 (en) 2010-11-30
LTPA2019003I1 (lt) 2019-02-25
JP5905934B2 (ja) 2016-04-20
JP2011504935A (ja) 2011-02-17
CY2019010I1 (el) 2019-11-27
HRP20140950T1 (hr) 2014-12-05
MX2010005776A (es) 2010-08-31
JP2012184234A (ja) 2012-09-27
AU2008329673A1 (en) 2009-06-04
KR101411806B1 (ko) 2014-06-24
US20190142805A1 (en) 2019-05-16
EP2217577A4 (fr) 2010-12-08
AU2008329673C1 (en) 2012-10-25
HK1172326A1 (en) 2013-04-19
CN102643241B (zh) 2015-01-21

Similar Documents

Publication Publication Date Title
LUC00103I1 (fr)
CN300872527S (zh) 编织帘片材(0602ptg-5b)
CN300885767S (zh) 纺织面料(33)
CN300907542S (zh) 包装盒(儿童蚕丝被-c)
CN300881793S (zh) 内衣(美体修腰塑身)
CN300848393S (zh) 羊毛衫(6)
CN300847771S (zh) 汽车雨刮臂和雨刮刷总成(主c02)
CN300822051S (zh) 弯连杆(2)
CN300811788S (zh) 妆台(56)
CN300807956S (zh) 羽绒服(16)
CN300793186S (zh) 接收机外壳(be-5012)
CN300791084S (zh) 标贴(1002)
CN300786835S (zh) 纸餐盒(8-1)
CN300767702S (zh) 顺挂感应器壁灯(双层内弧dc235)
CN300766361S (zh) 摇篮车(得月仙子)
CN300755388S (zh) 袜子(ky-0705-027)
CN300753839S (zh) 壁纸(83)
CN300732947S (zh) 电子涡轮强化增压器
CN300731595S (zh) 妆台(爱尔兰tw-809)
CN300731571S (zh) 衣柜(时代印象-602)
CN300731295S (zh) 压花布(j2899)
CN300731145S (zh) 手套(06)
CN300731020S (zh) 安检冬装（单排扣）
CN300730968S (zh) 矿泉水发生器
CN300730852S (zh) 蜡烛(191)